Preclinical characterization of an EGFRvIII/CD3 specific BiTE® antibody construct for the treatment of glioblastoma multiforme. (December 2016) - Kischel, R.; Sternjak, A.; Wahl, J.; Herrmann, I.; Thomas, O.; Balazs, M.; Voelkel, M.; Stienen, S.; Rattel, B.; Kufer, P.; Friedrich, M.; Muenz, M.